0001193125-12-379620.txt : 20120905 0001193125-12-379620.hdr.sgml : 20120905 20120904211309 ACCESSION NUMBER: 0001193125-12-379620 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120830 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120905 DATE AS OF CHANGE: 20120904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardium Therapeutics, Inc. CENTRAL INDEX KEY: 0000772320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840635673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33635 FILM NUMBER: 121072130 BUSINESS ADDRESS: STREET 1: 12255 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 436-1000 MAIL ADDRESS: STREET 1: 12255 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Cadium Therapeutics, Inc. DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: CARDIUM THERAPEUTICS, INC DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: ARIES VENTURES INC DATE OF NAME CHANGE: 20000523 8-K 1 d406703d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): August 30, 2012

001-33635

(Commission file number)

 

 

CARDIUM THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   27-0075787
(State of incorporation)   (IRS Employer Identification No.)

 

12255 El Camino Real, Suite 250
San Diego, California 92130		   (858) 436-1000
(Address of principal executive offices)   (Registrant’s telephone number)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01 OTHER EVENTS.

On August 30, 2012, Cardium Therapeutics, Inc. (“Cardium”) issued a press release announcing that the Company’s Chairman and CEO, Christopher J. Reinhard, will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. A copy of the press release is attached hereto as Exhibit 99.1, and incorporated by reference herein.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

 

99.1    Press Release of Cardium issued on August 30, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CARDIUM THERAPEUTICS, INC.
Date: August 31, 2012   By:  

/s/ Christopher J. Reinhard

    Christopher J. Reinhard
    Chief Executive Officer
 EX-99.1 2 d406703dex991.htm PRESS RELEASE OF CARDIUM Press Release of Cardium

Exhibit 99.1

 

LOGO

Investor Contact:

Bonnie Ortega

Director, Investor/Public Relations

Cardium Therapeutics, Inc.

Tel: (858) 436-1018

Email: InvestorRelations@cardiumthx.com

CARDIUM TO PRESENT AT THE RODMAN & RENSHAW

ANNUAL 2012 HEALTHCARE INVESTMENT CONFERENCE

SAN DIEGO, CA – August 30, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq22/cxm or at the Investors section of Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar. An updated investor presentation is now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen® topical gel for wound care management, recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause

 

-1-

actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linée®, Alena®, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

 

-2-

GRAPHIC 3 g406703g75q85.jpg GRAPHIC begin 644 g406703g75q85.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`20$P`P$1``(1`0,1`?_$`,L```$$`@,!`0`````` M```````'"`D*!08"!`L!`P$!``$$`P$!``````````````$"`P0%!@<)"`H0 M```&`@$#`@0!`P\("P````$"`P0%!@<(`!$2"1,*(105%A7M]=X.1I!,B0W=UB8.J%RLC-#);5V.+@9$0`!`P(#!00%"`<&!04````! M``(#$00A$@4Q008'"%%A(A-Q@9$R%*&QP=%",Q4)\%)BLB,D-'*"4V,U%L)S M=!<8\4.S5+3_V@`,`P$``A$#$0`_`+_'"(X1-6V;W6UHU"KKF>SKE*OU=X5B M=_&4YN[;R=]L1`,"::=?J#5899^==0>TAQ(1#J`]R@`4PAJM3UO3-(CSW\K6 M.I4-VN/H:,3\W>N[.3G3MSAY\ZLS2^6FBW5[`9`R2Z+71V4!VDSW3AY3`T8D M5+\11I)%6*0>^6\VRQI0VH.B+^M495HF\K&:-L;6\QG!3[%P5PDD]BZ+&0[N M+I]@=5.T#%YHX=>US4W'\*T\LMJ`MDN'>6'`UV-`+C^G:OIC4 M^F/IKY/MA'/CF;%><2!Y;<:3PS;,U":%[:$LDO))6PLH*@YHF&ONUH4I]>I7 ME_>03QW9LZ:3P=@^DM'$7#1F&\ESC!295*!GD9+S"MYBCLV33KVEY)%$+20.>[:8Y'QAH^V2M,E\G^7[!2,Q,W'!&M^W569)I/ M"H8/M-HQ9D'L.W(59G&5RWM;"SEA9N"&,/:8RZP'`"$#M$1M377%E@'/?;V] M[$,?X3C&_9L#7U!->_'N7([#@SH)YEOM]/T#B;B_@36I"6YM8MK;4K&H<:.D MGM70/CS-H,0&,H2YQJMQP7Y9=.^6KGN\O4-#D%V1&&AP?<6L1?+`2#[H,H!!JX5% M906[AN\;H.VBZ+IJZ12<-G+=4B[=PW7(55%=!9(QDUD5DS`8IBB)3%$!`>G. M5`APS-Q!7QA+%+!*Z"=KF3,<6N:X$.:X&A!!Q!!P(.(.!7[?LMQ[2*4KZ. M=$O1#=<\;C_N=S1;)I_)6P>7'.XPOU-T0+I(XGU:Z.TC`_F;H%H`JR%QD:\Q MZ?X^?$X>#E4ML-]E7&;=I+BJ-A1KU]>EML)C7Y_M=()2;=X9U&SEO9^H)0*` M'C(@.B3-(IB`H%KA[A-K*:KKU9]4?XJ/\097M!J"[Y&[&C"JWO55UQLU.R=R M.Z86LX0[(IYBE*4H%*`%*4 M`*4I0`"E*`=```#X``!SGJ\QR2XU.)*^\*$<(FC;@:2X%W:QR]H69*JV[$`!9(P@42Z?6=#L-)I[CO':TX'>%WOR#ZC.9W3GQ='Q1R_O7MMB]OQ5E(7.M+R.K2Y MDL5:!Y:W*R=F6>*I\MXJ0:[6&]N]J/#;G5AJEN*K,Y4UEEWB2M%R&*DE*O(& ME^NJR3M6.G;M5PZ>P46JX1^LUMPJHYBRI=&92@HF5?KJRUC5N#[\:3J]9-,K MX7;2&;`YAK[H^TPXC=3`'UDY@\AN2?Y@7+.7G?R!%OHG.*",B\L:1Q-FN\H> M;:_8T-:R:0-=\)J#&MCN"ZL[G%CS';$KEC@;?`0UJJ\LPGJY88QG,PZ'2IY'3WLS< M3#96X\RX>W]MS0(H]WF2,K@JV/A9U&>;A9@S=N;G>4EIU_7;!+-ZK8OFCMY- MYG6WLEY.7OZ!A352!QC^.DD%(PG^8U?+(&(7HU*7G6W!ND.UF\GUB^<2YKC1 MV\RN%<]>U@(R]AIV+U[_`##>>]OR!X!X%L@[49RCK9CJSR-?D"+V=8I7 MS5%3U8><9G,V`'$=/PZR#QNJ7J51)8!`1YI[S7^*;"Z?97%U,)HW$&M-VP[- MA%"#V%?3_+?I]Z/.:?`>E"N&YM"U:SCG86VX.1Q%)87#-X9()0^*1IQ M:YA!"<;H9?O*+OSE68QU1-V\E4V+J,$A9KM;K#:';PD-#.GP1S,L9",T4W4W M*/'?4I$O5;I%`HF.J4.G78Z%J'%6O7CK2"^>S(T.<30T:33`4Q.VFP88D+J3 MJ8\R3/);#&QM"797N)(#6. M-58[UC1WOUOQ-FW'^Q23O:2VT=K)VS`F4:S)`[E,J-Y@ZK=E0+:RE$F#ZN34 M%/F25]951TB$4Y.)51!IVF[#TW\=T^TGAU+^;N&$NB2?.1_3)S=XZX9#"F![;M#.;R2\U-0YY&ZY1Q%CB1EHB'HE>=N2+NOL M-\JV!I-1M9!R(*M?EF8(,D!.FHL("'.+ZE:<:6&G.U)U\72-JZ2-FQ@K7P$C MQ`;Q04`PJOMKDAS5_+^YB\S;'DQIW+:"VTZX$=IIVJ7[(I9;V=K9X:]L8(*@Y_P#TLW]Z=?TNOH?DYPK_=?$?_ M`-R7Y/J7I'_X?=+M:?[$X=K_`-,/K4ZF&-+,];_^,"XWO9V]WJ_YNL4M,Y4U M4DKM,+.7]8AZ_!"QB&*::B2148++BJ+GYA,W<55N=DY`0,DGV\SM-(U#B/AE M]UJDCY+XN<^`NP+0!0#9[LA!)[1E/8O-3F#U#\L.ESK-T_ACDUINFZ7RXM(( MM-XECLX@UEQ+/-GE>2":S:6#'D<*%KQ<0['OKT?;\;MSCAU/Z.9+DU#I0<9* M6S!_U(Y".XI&/?K+7S'0*+J%67(RG/3(H+7J1X/A`DN9H[;6/+!+92]@%E?T`+6ES6> M1,\FDCC`ZI<7$VG.=IKQ251CS;>>/:75[<"G^/7Q_P".*M8L]O"8]^YK1;JX MZNS^5M>4VXK4O&-`I7SL''+RSMA(,'BLDX=.4^]P#+/F;1Z.7-6(\7C5N[&/D'&#TY!@+E(B MPL7R;7$CQL1XT$_IJ@FLLF!RCVG.'0PT_P`S^RKP&B4Q\XGU+L_AK[Q7^6C4 MS]MX6_J&@6@>7' M:7'9L^?%6+>75@J&SS>>4:!\7VGTY>(%_%N=C,J#(4/72KOTV[Q,UK.T!27O M\S'+]R:U5QO&+`^<@H4R3EV9JT-T!P)BT2/#&UW[O2LFTMW7,XC`\&UQ[&[R M5![X-_/)M3DS;9?3'R=V$A;=FZ`I\[KE;)R@5S%T@SLDU74;)!4N6C(*(@FK MZ-R_4)%M)U]VHD*AW)2H%$P/42DHC>ZN23WUD7=O!Y?Q-G7X>M#4[#7Z:BG< M-AVJZKR\M/I+.NL%T94/)I\^8FHXSKZL5VVH?;=H&Q_6F/T MFSQTG&=[H8]+HKZ7JD`H]I@ZCRU,\L9F;M6=IUM'=7(BDKEH3AW*!S3_`#=[ MJ[>;`%,V9U_SMKC(XKOKJS-*\ZMT1ABJV`ZU2LLK4IGYV#-BJ2%F0LS"N"I" M*QA42`I^@`8`Y::^X>W,W+19\\&D6TIAE\[..\;\4YG\-?>*_P`M&IG[;PM_ M4YRK^9_95JFB?YR9[LIY5?<4>(JV8KF]^(S7O+N,LBSSA2/1C(2GJL+0E7V[ M9>RTN&O&.V=3DJG.DC5RN"*/HAV0IS`@2H45$P#\T0NR/RQE[5A6EN);MMO,"`2:[ MCL)5>71G:;W2'D3PL[S]K-GK7V4QRRO,_CM=S>*]AFFS066LLH9_*I$B#8NE M1,Q(WGFXIK>J'>83!VAV]1LL?.\9FY:+9W-MI-K)Y4WG9J5P(.!3R/PU]XK_ M`"T:F?MO"W]3G*OYG]E6*:)_G+"62']XGCR$D+NI<];66E23^76KE]J**"C@ M12]QA M7]!(O,$4CJS(;*X[Q\YQ^?'-!6?FJ=@QG'6&4C2V]2`&TE,O++G5!8'7K$Z] MH&`H=.6WRN;,&"F4T65:V,$VGR73\WFLS4QPP%1@MG]RGY9][?'KLQK9CG4_ M+<5CNIY#PA/7*UQ[_'E%N2LA8661#0#=ZF\MD%+.F94XOHGZ:1RIB/YPE$WQ MY5)(YKVM&PJW9VD4UK-.^N>,88X;"/HEHZVA>>0\^2(\=LT<3!:4\B_951"/" M:_2%:T3YH:8$0%3$GVNH+?T_E.SN'U.G?^=P'DPY_M4JI=;QMU'X7'RO,#>^ MAHF?^WV]P5ES;3-L]J+OI=ZS-Y*OH*3>N^2&=:K]'3GI.,9JN+'BF<8U]I&P MJTLNP0%_"KE135<`DX;'%13T.M,,WF"CO>5[4=.^$<'Q5,)[=WK^;>KFW+ZU M2.$4+'G!\K5=\7VJS^;J[^&D=H,MIOZKKY39`B+X&\H"9$YK)D[%*#T\1MS%9-K;/NYO*9MI7U)D?ME_(]M_Y$L>[>3FV M^2V&2)3%-\Q1`TARPI-/I81<;9:M:)*:361J,/$(OU'CR.1/W+`<4^WH3M`1 M#E$+W2-)=MJLC4K6*TF;'%6A8#CCC4CZ$G/N2LTOE+7KO@!JN(0L7`6/,-@1 M173-\S*O'BE2KJ3I!-452'CV+2043!0@%-\T!BB(E'MZMYCWCC<6]@/NVL,A M[R3E'L`/M7MS^41R\M6Z%Q7S1F;74IKJ#2H"6^[$U@NIRTD4.=[H6NRDT\NA M`KC-]XJL.(X0T'USJXI-"RU@I#;(]B<-$O3!Y-Y%54MJJBYNXQEW#5C)H-1. M/3J5N4.A0`"AS;A2S%EH%M']IS,YW8O\7R`@>I>BNQU^QTZ@*-L936IV\?9'[ M`WT_(U;0;KF0HMM=ME4E6XMG1P/&R)BK"R.8Z9BBBJ8287%'"T>N,%Q;EL>H ML%`XC![?U7>O8[=B-A79W13UK:ITU:M-POQ:RZU+E+J#PY]NQ_CL+ASFYKVU M:X$.S-!%Q`"P3`->")&#-5%U5V4S_P"+G:&7E)>@R<;/1J"U+S%ANX`YKZEE MKP//71*A(_*NBMW+-^V^9B)9!)VS6()Q("J*PCSJC2M3O^&M3+RPMD'ADC=A MF;7Z\6NH1MI4%>X'.WD_RMZT.3,%E9:G#-IDSA=Z5JUKEG%O/ERDEF9N9KV. M\NZM7NBE:0W-DDC`5V+5_P`@6NNTF`)38BNV@E&I]05&-R:ED,Q*V7'%A1;- MG+N$FYQ[Z->?F33>HBFX9.7""WK$*`@H;TP[ITKB'3=5L':A$[)%&:29\,C@ M*D$[#MV@D>O!?G2YS]+7-CDMS2AY4:M9'4M?OQYFGFQKDGAF.12HB.7:.T M8>HQ2O8_@ZBXD&O>Y=O`2=/T2`F5%)$YS*=<\5<8LU2%VFZ<"+,GQO/VP-S1 MM#:XDG$TI0`KUVZ(?R^KWE'KMES@YP/BEX^AC#[#383G;I\LC7-,MU(*LFNF ML=2.*+-'"\EQD?(UH9I_BR\.MMV3D:UGS9*&?U'7AJX;S%;IK\BC&SYI%NNY M!$%&PJ)OZY04WC0IEUETR+RZ!@(V`$%#.`L\+\(3:FYE_J`+--!!:W?+ZMK6 M88DXN&`PQ7(.M;K\T+E!9WG+#E%<17_-A[717%TPA]OI&8-K1U"R>]+7$,8Q MQ9:O!=-_$:(C=*9LV<U;,6#%NBS9,F:"39HS:-DRHMVK5LB4B+=N@B M0"D(0`*4H````!SNAK6M`:T`-&P!?GBN+B>[G?=73WR7,CRY[W$NKM;H?&#IHL(V7#):?LOHYPW88N'<%^F3D5. MSJ7Z`[;A_6"9[^[X8O-)D+L7?$Z=YD-J_P`(-'CR;61N!CT]U[AX0^`_I#Z!?P:QUS&E^_9^F];K3_],N?7^ZO1QYE+ M1(X1'")/LL94Q_@[&EZS#E6SQM,QQC6KS%RNEHEE138PU?@F:KY^Z.!"G65=E)&EJ-@U%4ADFSFRY!?ME)^[.4RF*BP$&8B4JS+K8;_%?G/NC9WE; M:4_`VYMV'^/)[W:&]F';M]![E*[[FCQ5.6BXO8W$)XJB[!U1BHFFFO8!C2* MPN2X)D4I1;U+)31!5VW3#O!F\2=-!,?T"J*2QX>W,%:NK9]K,8G^H]H[4R/W M;_\`=-H?VJL"_P#:M_+=S]UZPL[1?ZX?V'*#[Q->>C,FC^BF(];:AXR=@]CH M"C2617;3+U$6O"=7LJEJR'9K6Z;QY8;#-PCO4@G$T9BMZ;]8?5;F[@(;J0MJ M*7(P-RN*S+^P^(NG2^;$VM,"<?\`LN6'^%?Y\/M4 M0/D&WAW`]R([UYPUJWX^<@5]CBJYW.02M+"T/;I5'4_9X&)CI!I<,D/:;2<< MX_CX"-9E<'!X_.X6!4!`I?S"J4NSS,?8;+AK#>K^/K!-1*"S>*D9NNY/Q@QE5XQ)P<[C MZ?\`/)J%1,<0.=,`,)2B(E"N4982/TVK$L)/-U-CZ4J3^Z5Q]HO_`'5ED_M< M9F_@MBWD6WW?K5[7/ZP?\L?.5:)YD+3(X1><=XW0#_%@Y;Z```&P^]8@```` M'_D5U_(`?`.O7F(?ZH?IN7(H\="=Z_WUPS!_S?-2_MDXA_H9B>1+_4-]7SJ; M#_1I_P"_^Z%NGO)__FCIM_9HM/\`2Z;E4WWS/3]*LZ=_IUS_`&3^Z5Z!6-/] M7%`_]DU7_P!"8XMKI']4/4FQ1O M_)D2/^P4/_MHQY#?Z;^ZJI?]:/\`SA]"KQZP>+>];!^)Z[>1;6A]9D-D-2MF M+R>R5^N&<*R]FQ93JIBRY1UII?I*BI&7;$DF_>RQ2))*#(,A4#IZJ")5*(V? MP@]N#Q59=[3S65",NDFP9;6X0BH M.`S97BG31/<6)VB+6#S176R9"H&KUU715(Z22,86$HDJF.[;9:-C:`D4U&R8U_%TDX1EK M._23.,O/.Q0*)2"L"-D`2@O=[NX?2MHY[M/@#\.=,\P?\`73_T[/GWM_";'/;V].WI]GPW3MZ?#I^MSN33Z_`05V^2S]T+\_O, MZO\`W)XAK6OXY?\`_P"J5*US+7!U$9Y<<2Z%2F$"9BW&AG3-_2I&.;TF=H3A M*&RU<9`7:+W\+H-XD!0FF5K:M%6JA7W.NIVRYD'E_R`N(Y+;48GNO(;UIFTRT MCREGXC,P_=/MG.;(##22YON&,;.ZGAB"?$CL, M:JX7\.:#HUOJ3;?59XY=6`S-A&+&GL<[W7O&/@!PI6AVKX0ZO>J/J(XEY4W M/$O)#AW6=#Y&RR_#S:_-'Y&H73'9VF2WMB_XFQTZ890R\="V1Y.7S8LP8;;B M22:*::**9$D4B$2222(5--)-,H$(FF0@`4A"%````````YVR``*#`!>%#WOD M>9)"72.)))-22<223B23M*Y\E4JC-Y_2,$_(1+GAUG2\NIAC&!Y5!VFF1JWE M"#8"1B+`X`7U6JS`J)U!./4%3'#X``>/`1YIA!J9%19(S9*0%0I!*9[_EMKZT*?AY_U'^P_4MVQ_ MM1K!EFR(T[%FQ^!LEV]PT=OV]5Q_E_'MRLB[%@0JC]ZC!URPR4FJT9)G`RRA M4A(F`@)A`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`.Z$K'O+:?:$-G=+LAJ04C]E.\&WFFMK&5N8T8M:HO(C6PO8`'(?L:TTKOP(^E7!==?);X_ M\DX.Q;<*[N-K@TC9.D5HOR-JS%0*;8HUXUAF3=_%S5;M$_%345)QSLAD5TED M"B50@@`B'01OYF]H6I$$QP#'5'<4M'Z>6C?^^;JA_P`1.(/XX<9V]H4_#S_J M/]A^I53/=A;NZEY9T[PQ@K$NP&+8M]-3\ MO5Y"3BXE0S-N07-<&]I%!ACO6W M3-/M-%]F^^@;C`R5;FC:X0,V$7+MCLWP1-FV:@[%`/E&JO19!*5@Y-NZ2!0I M3BDL41*'7IRK*6P93M#59$K)M6$K/<=**>T)=?:!(HN?&CF-NX227;K[>Y(1 M7063*JBLBKC/$A%4E4C@8BB2A#"!BB`@(#T'BW^Z'K35\-0<1MHWYE$!Y+=: MK+55= M10Q6KM`"$.469"#2_P#A.\QNPX'ZUY4W:P+H9IJ>U4K4RK,87)60+!9(TC(K663B$7MUR7=FS0\@F"..VU^[/I6 MWUW^K;_8^DIRGN2\1OT+_KEF]!F'T6KN8]H\7=M>T_A.C=&3W@YA[03[%[=?E#\=VDO"O% MO+B20_B=M?V^IQ,-36&6,6TI;4THR2.+,`!C("2:X3P>+W*;/+^A&LEJ;NT' M3R/QG#TF<*@B#<&D_004I\HT.AZ[@R9TUX;N`3&[CD,!^A>[H'.^%[MM[H-M M*TU(C##W.9X2,?0O,KK0X+N>`^J#C+19HW,@FUB6\AS'-G@O:74;P8-.^8D#>;%/C.T%Q5K)J MG`Q,E`0-FR-FVB-I7,US%J!GE@8W.*!W]D,I(`(_;U""BI$K1)%-0A5E2GDVF;P0/M)^^`R>/G>.RT MO$,\_:1M!E:3ES$DF=VJM.UQG)E2L,+'OWY@(HZ?PMU$SAJ4AC_G'. M`=0ZY8C0-_JGZ;;+B+CVUB?=ZI!> M:9J<8:!#<.C)MYI&,Q#631.9)DI1DA-L>W=VT(P=7*CU M.U.6*9Q4(R<6&!82ZS0BAB)F4(W4>"0#"4HB`=>@?DY]`6TIGMXYC@7L:[V@ M%?EJXRT2+AKB_5>'('F6#3]2N;9KR*%[8)GQ!Q%30N#:D5.W:MXY>7&U0[W, M8*P46J*#*1MBSA1<'Q*I'!GK,E>QV$9`6]\BHF5$48Q-2)EW:@%,()B M900/_E#HK6J:[Q>^VAQC?.V+M%&`->?1@XK]-O3U"SILZ";3B37&^3=V?#=[ MK,H(R.,U]YD]JP@UK(1+:Q--,:-&57O6K9%FV;M&Y`3;M4$FR"8=1`B*"94D MB!UZCT*0H!SO1H#0&MV`+\R\TTEQ,^>4UE>XN<>TN-2?:4T';O0#3W>VO1E= MVJP12,M$@$W:=7GIAB=G<*D#XR9G8U>WQ2K*Q0A7)D@]0B#@J2GQ[RF`1ZG- M#A1PJ%$4LD+_`#(G%KQO"AA'VE7AX,)C&HV>!,8QC&$<[641$3"(B(B+/J(] M1Y:\B+L6;^*ZAL\P^P?4OG^$I\._[Q<[_P`^MD_\N;D`3NS`5IL&VG93L"4W2'PF:*:`YPMFQV M#JYDB9S+?"T4`V`;]REOY4K2.$33MU-)]?-_\$3FNFRM5=V? M'DU*PM@04AY1>`L]#'$ZH@[=+*E[3*&Y&1N7)3PJZ+F<3FY#CYQ-:_IA M3NV;D^C333_#6B&O=,UCP$ULK/%M#>6A]7VUNL3JUSR:UOL\O;I@'/LK[)5>_?B'C.O+5:MVO&V0IC'TJ>&&9)8(]O++1)%`DE(&9]1PP4.`':J+ MJ=H]#=`I6%KF1FC7BAP&(3J-HM,\.;B:NV'47.Q[I9,4VN(IT M18G3&U.H>[2I:1+P<]$R#FU,T0K[2_P^+G]1>DY[6/T`O>KGBS*'[0Z]"]QV@CT#K^3EKR(NQ9W MXMJ'^(?8/J7Y_P"$I\._[Q<[_P`^MD_9)CZ3(-GXQ,UF^UN8>4*W4*H:/E6S8C-PXCW0!V*D(JF8Q!$`,'Y>3 MY$0W*#JM^10R&GH'U*;/5[3;5[2VF/Z!JYA.BX8K,R[92-A;T^)(U?VB5CV1 M8YK+VF:7.XF+'*I,R]@.'BZR@`8W00[AZW``-BP7/>_WR3Z35,IF_"=HU8=] M6GDADX;**NS+'(,'DQM(DR9,)TDEHKM>;5B,/]F`A]/%@G%M2@9'NZ'4ZF$? MCTY!8TNSD>)76W,[(3`QQ$1.(&^N!_\`38G^[#ZT8$VRQL_Q!L?BFG9AQQ(O M&DFK5KI%)23)M+QX*A'3<6MU3>P\Y'>N<6[QJJBY1$P]APZCRI6._>H(ISVG M_AYG9F4F3XXS1&C)OW+TL9%9PM2$5&$<*F5)'Q:#A-TNA'M`-V(D.JH8I``! M,(_'EHP1$UHM@W5+]K0T2&@'8#\I"Q7^$I\._P"\7._\^MD_I#)LFV78/(N/S==9K)=:AY".5560D&=8E!; MPCAV*IRF$7:+D@&23,4I3%Z\J;%&PU:,59GOKNX:&RO):/57TTVJ5[:K5S$^ MX^NV1]7*@;4PJDRM5Y@8V&GH>QL48N79)F6C?3D8)OU["_%(! M)TZ#RL@$4.Q8S'NC<'M]X;$E&@WCUUS\;.(9_!^LC"Y1U#LM_E[V]_= M)0;/,PT!!/E&\I(IIKH,3,*VV[40`2E.!C?E,/#6AHHW8JI99)WF24U>=Z6/ M:'63#FXN",B:XY[JY+;B[)L*,/88PJYF4BV.DND\C)N!E$RF<0UB@I)ND[8O M$OV1NY2*<.O3H(@$4.Q4L>^-P>PD.&\)L_CZ\5^G7C*@;[#:LT>9B'N2Y5A( MW"W76QNKK=I-M%-0;Q->^YI)%-^C68I4ZSA!D4?2(Y=+*?$Q_A#6M8*-P"N3 MSRW#_,F.9Z>1FO$=.S]A_*.#I*\+*R%1CI.+ASQR\DDD>/3*TEE04*7J"@]H_#M#E+6M8*-%` MKLT\MP_S)G%SZ46\^0_4:-W3U;OV'P39(W5)`ELQ9,OC'31A,B0!%EH1991/ MJ)64HDHLP<]0$/EW9S=`,4HAIN(=);K.ER6F'GTS,)W/&SV[#W%?1?2CSWO. MGCG3I?'F:1W#CG?#:E"RA,UA,0)@`?MQD-GCICGB:-A(-?\`\#&U\OA/+V0M M#LT@_J2UHLDK)4*#L3<[%Y6=MKPF4$/F4\7U M@W!AH3.>"F+%UGBA0BL!,U5V\0CDLGT1`[I^WBV;MP4&R5N@7CA4S#UE$D7* M+A5$YP-Z/3@O&7#,NKQMOK$`WT;:%NS.W;0$X9@=E2`14=B],_R_.L[2N0=_ M<\MN9IW(GBN6L=(=.O2&L=(]K3F-K,QK1-D:Y['L9(UM/,JD.J'DSM M.FFEL;$^0:HS%,O-#:I4_`M47,U;Y?S!4X!H]8LPL-&67^I4AE6%(U-@6?ED MV4=)-0341%98I_4P='XG?H^BM9Q`TQRQM#8@<))&@$#,PXM#:4SNHTC94U7/ M>=_1SHO4'U#S7_2Q?0:APSJ7I[GU-<,P;2D; M1@5T\SBZ9[BYSCB2XFI).\DXE,0\D&XT) MI5K!=,D"\;FR)/M7--Q%!BJW%Y*7R9:JH,)(&:I_56B:J0XR#XY2'(1-$I#= M#*D`=#Q)K+-%TQ\X(^*>"V,=KR-M.QNT^S>%]-=(W3_J743SET_A(1N'"=H] MMWJDU'9([*)P+X\P%!+1"TD$NBKAR[[3?L?QX-P!H\DL[M=G]P9 MFL_:3O"VI-]S5C_(]1R"]D,-:GO-KC2$`QB7;" M\Q#.TO:F;&=0(K)HOG61W#U!%5%LHB1NH@Y`P*]2&*!2`"14[5M.?MZ'F(Y_ M5ZE8[URRIL1?MJJQ>[C2ZECNQ8NKRL#7,=UZD6.Q2=CF\D76HU\B*32^,R)@ MW5W'FK&>Y[$F0L%9KD<>X\C=>)+->P]71I,GC M3"K?9ZUW2C8N>7B,6M;2[FA%+52EF\E(LHUTSC2+)JK'`H_$A`I6N].-=[?I ML]VVVF*V'KR05]?GVQI\Y'G*"GC%K28ZQ)5!VV<,U+02Z$E$K.Z1:B'TWTNU M4%N_T2F.$J`!0DE8O3G=J*W3962[8^PMENL8.,M(+8?SQ=&U584C/$#$V.6J MJ2A.L54EH`K4']/F[UB]4?(3AK; M^P;:5W&D9:&;K4?+,QBZT+SS9FV;7IM&,7:S3(5".BZ6-)T2>E(>3CV3Q0$_ M6=1;@.G:4!$#45"ES"QV5W=W[<4OFL&?*]M+KUA_8JIPDU6ZUF2B0=]A(&QB MQ&=BHZ=;`Y;LY48QT]8?.)$'H?TE5"=?R"/)5"9YNCY3<.Z5Y&)C>R8XRSE. M0JV)1V)SO)XLBH"4C]?-=$[JSH"^7K^G+ST0_?QQ+"Z4$D9%)/955BR=NBH" M@V4,!2!VX!<=N?*!0-3+U4JT\P]D_+-2DL$2VSU^R;CA]0C5?%F!8"[T^D3> M0YMG9;7!3UE:,'5V9N@:0C:0?+->XR:1A#IPE,":XK]MA?)Q1M=]AVF$9W#. M5+34HNH8"O.4,ZUEQ2?L#$M=V5R_-X.Q6^LL-*V:.ODT65O\-Z"Q8>,?J-D% M@6.4"%.(145IO4Y'90XTRFM,>S;\ZQN=?+!@W`NR,E@&>HF4K)`T"RX%H^?< MZU>-@'>*]?;SM!++PN"*QD%5Y/,K(X$L>): MU)0!;:GDD64TO8F;!>21AU6+-TN3U3E*8#`S]+U'G[N%2D_KOEBP%9\G7_#\96KR:^XSWSJFA-M MA54H1-5G<+Q7Y:P57*"`C*C\UC652@GC<%2_Z]3Y;JY1M MRU]5*_,E3@-V;%:L_;?Z]5S5[+LK:-3:-5;B$NG9<2MX/,;R_P`.[FJ!5*"H M[O:#J+FK6TBWGIJ3B<:T:F:F^951[T^Y7&B@MHW,DCQKY-GV0],\_P"Z:^H> M=:E2L%M+R_0IS%*U3JF$\FY0R>_H-)RMEI"GR>.6S3!>-<@VF6H]9M]H3M-TK\C;V![5 M7I!!X6MH2JC%%H*ZP%(JAZDJDB@K4):MG\^5_5K7K,&Q-J@IRSU[#E$G+W+5 MVL_3_N";:0C85S1D.,J[81H/WANA$Q7722`P]3&`.H\*$S8OE.Q1`:P9NV*R MQB[*N)K!K_E=G@B^X#G$:C8,JJYDLAJ2./L?U=2I6:8IUGE[^VR1!JLCM9(Z M*)'IOF#)>@MVD.W#8OC;RE8V5U"S]M&\Q#EB&M&L.0E. MUHV(SW^BKGA2Y:C7*6JFRNOBTGBAGD?&;.!I3'),O;4IQ>_?AW5],<[RV3MM;])43&VO\=;L'!>V MHLZ)<,F,[!/V5UDI#'#&*E*135GI"!+F<(@L1-5,BH'(6*JHMQH"#@L3M7Y6 M<9:D6"N5*[X7S1;+5'X-8;-;!PF/F=.L"^K^!5;+%TR6R!DYP-J:M)8D-:9! M5`6,$>2>.FT<]=H$.V;**<5"!CB*[OG/8$[EOM#2)#9#'NN$3'2\M*Y*UTM6 MRU=N[(\4EU\B-'382(&;BV24[CE-VE-&89LN^E5 M6(G&$S890X-]9!/T+2)/<`(G=N/TR>88OZ7SV"9C8)3.BDS04<7L*7!3#>M2 M:+]JM:4[HWD&UG?-V0@,;Z?5<%>[T2G4+4K20G4/RLX2W"R\GBJI8_RO1&MV MI-ZRAKOD+(,1!QM-V4QAC&_%QI?+IC8\=.R4NS;PEJ51%-G+-F+UY&KD?(IF M;]3!`(*J7< M0S1N.9^GRM<7/8PE\+LSHVEKG!;IXY/+)#9K<--9]M4S8U"("+V)."::RX&49"=,X))W.'>+H[PC3-7K#JS/"< MPRAY'[K^UN%=K<,%Q[JVZ&M1Y=12TO=(UNMGR0UAU7S5G.%B@F[#1*>LYK$4=`[E%[:I=ZSKU M82=()G(HLS"=EFYEBE$#&2`P!\1#G)-WBL+[->W&3&*EH=+69)C-U3$T],LU58T6-7EF*\%8;'5DW22?H/D'$ M&T5;@DU:>D0JAN,:1P>TDZIK;C-K$@S8T+8W&M*`^%Q;78X%@(P;O7V7SZZ\ MKN%L?)KIMM(^'>16C2"W:+P5"3C6:*43#FJL MBHAZ3-N4K=J)U"HB+AS:I8:K-H6JRFX_A^=%*10EN;*6G<*&F`P&[" M@'7_`%'Z#RXRR_$L#\TK MR7R`,,@$HDT#*&$C=N!@,JH0OQYOM5UBPT:V-S?/#1N;]IQ[&C>?D&]?./)'D+S* MZ@.+HN$N7=@^XDSL^(N7!S;2SC<:>==3!I$;!B0T5D?2C&.."K:5/7C9;SA[ M%-=CLR-9W#NEM6EE8JAU^17,A.O*SO&I/K=B./H(B(I M-!5]%(A.M8=-U+CC4!J=Z##H[31@^UDVT9@023[[]GZNP4]>==YK\G_RWN4S M^4?+]]MK_4/>P"2]GC;FA;=FH9-?$OS1Q6[''X.Q'C=@^<,\Q[G6P:/2:KC: MG5F@4:$8UNGTZ$CJ[6X*.3])G%Q$4V3:,FJ0")E#B1),!.H'?$G$>M\7Z_><4\2W,EYK^H7,D]Q-(:ODED<7/ M<=PJ3@T`-:*-:`T`#:>75I%"ONKXPIW<_.F4,EVV4CX"*JN.L8FUX&`L#AL\ MM>0ZM4MA8R?K68F+F&=H)8Z5L.3(-ZB5FHHHHXBTUS$*HW3$:7"H[U=C<&.! M.+2144W`_2D[V,\=F=KY4_%.1GCK&>:7VDN&I>DY3I=AS[D_!C20N[S%F&ZG M#V6J7_&\&YLLPPA;)C]XJHTYN#7$T%.TU MIW4[EC=^/'?MUM-FC9BJT+\%(+77=+'6DF-\OY%M%OLY4\FY*NY: M%18VJNH>QS]M2M;-E&.'T@@U;*`HHLD8H`'*E;PIWIZ5BUQSC/\`D9/F@\!1 MD];'NC-CU:>V,EY?!D]*Q6&_L[Z>6;TL]1/#'C4/IY60&-)=PBH*PDZ%](8/ M8I::'-O&(]-5HOCOP#N=IAK.EJ19:W@>TTG6[%4W2=;6,SD)(3/O74;E*AV%`,,-REY#CFVN.)W8^C]/0FX M>.7Q@[(Z/Y35LMES"&7*EF32FN8VS*RL,G#-7&.-A:I>;3?(^.QJVKM.@"6; M%2S_`"Y;2_4)2\46&GN[Q5*B[AH&^T;[>H[E= MW&2RCJ+4D00$[)0"@8BFSN4EY.:M*N-3\ZW&\>.JJYC\D;W;S,E?CK;CNHX! MP)5,2UTEXND8W:Y?Q9EC+5]=SUVQW"O8NFW>)A$K1"NH3ZT632923=55%NDH M`*F@#Q$[E4YX,36?:!/RT^I,NVS\4FQ.9]A=IF%!L^+&^L^^F7=(51A7WE;N"&2X.E1)&#E\]:_2W:CL5R+)>CVP6`FO># M[%<;<.;&&=C7-&RE';?K68SOXL]@+CY%G&^N.;G66[B*VMU>O2>,[/<[0;'F M1L!TC!<;BK*;>VT4L<^J;7+=.L0KS-0E3-7+E,Z)`!RV-Z0I54QKO5C,2W(? M=%2/25)DIK]>#>1-KM2#F!_#9'2U_K\=F+QS]S_?#G.4;D9-R$?\G\F,#]!: MG**WS'J`XZ%]/M'NXIC7N4Y_X>3?FK\@3"\9:";1US9#'D79W.&_T9<-[V;( M;W5;(T-8[0?+5PE,YUG)T;"XGEL=NZY]NP1:M,YAD3/9=.77(\9QS;TD$E55 M>*5V]J!V7W-[:&OT>Q(U)^'S+KC;['VW$+<:Q7Y^"\E^0\_Y&K+6;?FA.1`Q&Y6JN*I% MQL,VG4K.NL049!V9$6I2CW>J)B2!0DJASLS6C>!3Y2?I2+UO378&C>*S8'4: M';X[GLX9,B]N8:LIO;5*15$(AL/E3)LW!/)2QIUQ[)-3PM3OJ;A=,C!3N>(" M@!NTWJ@`I7TJ7N#RW<`T#V)$]K="]C<\4/QEOI'$&(LBV74FMVYIE[$[W8W* M.(:^]L4IB:MT6NR-,RWCJK-;B]:1,]`_-J(*-FB+E`WI+$4+U`1'B!1KP(G1 MXU)!]E=OM2Z[G:<9GV*SIK+?L>T'#F.[)BR8QA8EMJF&2[[`YTQC'U6^1MMR M/BII6*_6T(7-.-"KALWI=L MMK[0%X9M=,O8EM5%K:]A?.HR$2DYQI\L@:2D635Z\8M@ZCU522.HF/Q*'4`Y M*@$@U&U,ZV4\6%2G]$!UAU:2BLVO(^12L9$?8TCMAO( M=L%6\T62F52V60<:XWK\!.8FBFE.C,A&@8NV2,V6BX\766E$F;;I)N2@V*B5 M,%.0:TP532T.!-:;Z''U+=<+^.3/6'-$O(YI>I<*S?29PG]F@UCR/:[/8)B\ MRM(SA0U&E1A<\VR9CG]AE+!0K!(+1022SB575B&R`@8"D(@2536M*I9MJ?'V MZVGJWCQQO?V<5,8[USR#&6?.$4SO-TI,I*1<3KI?,;,DZ98J0Y@[*9TG>9YB MJ()O8_U&1%!.80ZI&)4BH&PIMWD(\:>QV:,Q9@N^LDOB,*WMEH47QZYC;9I>PQN6J*$'#3:EWDFM;M\LT7BGZ[8ZKTC-8''I@X34I(QKW*XV M0"/(=SJ@_IZ/K3A+SK/L_B/9_5K+VM52Q9E>FX?TUG=1K.SRGDF8QM.-VTA? M,.ST?=(X(*BW%K+JH0^-5?6:C\L!EE@`I@#X@R^+-W457G5A,/:_-7T`BGRK M?[=KYGZU^2!+-[FO8\0UM=Z57+6F5L2%XE`R@G8[A=XR^+2K"F*5)2%^F-', M01B4RDD)Q*L*PD_-!,:E83'O'WXM]D->\XZM3F<;-BA?&'C\P)GK7[7Z5QY* M6*0N&9V&;[^RGDKGDJ'FX./C*,I6*9&),U6+%P\%U*G.L14K<"I<@`[]JN.< MS$1BC33;C\OI[E8*Y*MHX1,IVP\?&K&YL>8,S8Z:J6Y)LV:Q>3JJ=*N9*A4& M:_S+=!E:&S=19PS(H(A\NZ(X0Z&'H0!Z"&DU;A[2M:81>QCS:4#VX/%.QW9W M&H7T7R-ZJN=G3W=`\O=6>-!<]SI-.N0;C3Y2X97%]NYP#7D4\<3HWU`\1%06 M-R.FOD?PE6`Q_B#8_%.X>&GR8-G3 M%#L,X11*@JDFHD0G:($(M_W9VRK>WX\A95NX]4@G[2 ME63!,Y0!4Q@-S;F^XE94&PA>0*U;<"GH\4;37U=F)76%IRGZ--7S7%MS5UG3 M[<2%OE7O#,IFIM#@;6^EC6/*MOB)NO4/3#5U]]NO: MI)9+<6:WYYR/%UR5.E*/XF#1&J4R"*@>98-%O24*=,'"!3]YR\Q)XN++R4/B M;96CLF4OJZ9X!Q(!RL`%:;C0C>N2Z)JG0WP1H,^F:KJG,+C6S^,9VWM= M%L)+B,&)DLQ^)NYB[R7R-S-+26/+7?+QS*>1I;:W=7$^:XWI;&X&6 MM'ED39*5'FFI4P;5JU8MF[)DV;LV;1%)LU:-44V[9LW1(":*#=!$I$D44DR@ M4I2@!2@'0`Z